MAPK (JNK)
c-Jun N-terminal protein kinases (JNKs; EC 2.7.11.24) are members of the family of mitogen-activated protein kinases (MAPKs) and integral part of the MAPK/ERK and NF-κB signaling pathways. In mammals, there are 3 different JNK genes (JNK 1-3) encoding for at least 10 alternative splicing forms of 46–55 kDa. JNK1 and JNK2 are ubiquitously expressed, but the expression of JNK3 is mainly restricted to central nervous system (CNS) neurons (high level), cardiac smooth muscle, and testis (low levels). Besides c-Jun, JNK can phosphorylate a variety of substrates, including additional transcription factors and even some non-nuclear proteins. JNK is involved in many physiological processes such as embryonic morphogenesis and naturally occurring programmed cell death, while the unusual activated JNK pathway can cause pathological cell death and different diseases, among which are neurological disorders, type 2 diabetes, inflammatory diseases, and cancer[1].
MAPK subclasses listed: MAPK (JNK), MAPK (p38), ERK
[1] J. Cui et al. JNK pathway: diseases and therapeutic potential. Acta Pharmacol. Sin. 2007, 28, 601-608.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1291 | AEG 3482 | JNK inhibitor | €90.00 | |
| 2002 | Bentamapimod | JNK inhibitor, which inhibited JNK1, JNK2 and JNK3 | €70.00 | |
| 2025 | CC-401 | ATP-competitive JNK inhibitor | €120.00 | |
| 2634 | CC-930 | Potent, selective, and orally active anti-fibrotic JNK inhibitor | €95.00 | |
| 3625 | GNE-3511 | Potent, selective, orally bioavailable and brain-penetrant DLK inhibitor | €90.00 | |
| 2949 | JNK inhibitor VIII | Selective, ATP-competitive, and cell-permeable JNK inhibitor | €105.00 | |
| 2361 | JNK-IN-8 | Remarkably potent and selective covalent inhibitor of JNK | €95.00 | |
| 2519 | SP 600125 | Selective, reversible, and ATP-competitive JNK inhibitor | €70.00 | |
| 2365 | SR 3576 | Very potent JNK3 inhibitor with >2800-fold selectivity over p38 | €135.00 | |